Gene and Cell Therapies for Beta-Globinopathies

Nonfiction, Science & Nature, Science, Other Sciences, Molecular Biology, Health & Well Being, Medical, Medical Science, Genetics
Cover of the book Gene and Cell Therapies for Beta-Globinopathies by , Springer New York
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781493972999
Publisher: Springer New York Publication: November 9, 2017
Imprint: Springer Language: English
Author:
ISBN: 9781493972999
Publisher: Springer New York
Publication: November 9, 2017
Imprint: Springer
Language: English

Hemoglobin defects, specifically sickle cell disease & thalassemia, combined, constitute the most common monogenic disorders in the world. In fact, nearly 2% of the world’s population carries a globin gene mutation. The transfer of the corrective globin gene through the HSC compartment by allogeneic HSC transplantation (HSCT) has already proven curative in both SCD and thalassemia patients, and provides the proof of concept that genetic manipulation of the defective organ might be equally therapeutic. However, procedural toxicities and the requirement of an HLA-matched sibling donor limit this approach to a fraction of affected individuals. The editors review the progress & the state of the field in HSCT for hemoglobinopathies & shed light on the major changes expected in the next decade. Although allogeneic HSCT is a curative option, it is limited by the availability of matched donors, which are often available only to 15-20% of patients. An alternative to allogeneic HS

CT is genetic correction of autologous HSCs, to overcome donor availability & immune side effects. This Book reviews the progress made on additive gene therapy approaches & the current state of the field. Finally, targeted genetic correction is emerging as a novel therapeutic strategy in the hemoglobinopathies. Although ideal, the inefficiency of targeted correction was rate limiting for translation of this technology to the clinic. With advancements in zinc finger nucleases and TALE endonuclease mediated targeted correction, correction frequencies in hematopoietic stem cells is now reaching levels that may become clinically relevant. Furthermore, the ability to generate autologous embryonic stem cell like cells from primary somatic cells (skin fibroblasts or hematopoietic cells) of the affected individual has allowed for the potential application of genetic correction strategies.This Book reviews upcoming genetic strategies to reactivate fetal hemoglobin production and research advances.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Hemoglobin defects, specifically sickle cell disease & thalassemia, combined, constitute the most common monogenic disorders in the world. In fact, nearly 2% of the world’s population carries a globin gene mutation. The transfer of the corrective globin gene through the HSC compartment by allogeneic HSC transplantation (HSCT) has already proven curative in both SCD and thalassemia patients, and provides the proof of concept that genetic manipulation of the defective organ might be equally therapeutic. However, procedural toxicities and the requirement of an HLA-matched sibling donor limit this approach to a fraction of affected individuals. The editors review the progress & the state of the field in HSCT for hemoglobinopathies & shed light on the major changes expected in the next decade. Although allogeneic HSCT is a curative option, it is limited by the availability of matched donors, which are often available only to 15-20% of patients. An alternative to allogeneic HS

CT is genetic correction of autologous HSCs, to overcome donor availability & immune side effects. This Book reviews the progress made on additive gene therapy approaches & the current state of the field. Finally, targeted genetic correction is emerging as a novel therapeutic strategy in the hemoglobinopathies. Although ideal, the inefficiency of targeted correction was rate limiting for translation of this technology to the clinic. With advancements in zinc finger nucleases and TALE endonuclease mediated targeted correction, correction frequencies in hematopoietic stem cells is now reaching levels that may become clinically relevant. Furthermore, the ability to generate autologous embryonic stem cell like cells from primary somatic cells (skin fibroblasts or hematopoietic cells) of the affected individual has allowed for the potential application of genetic correction strategies.This Book reviews upcoming genetic strategies to reactivate fetal hemoglobin production and research advances.

More books from Springer New York

Cover of the book Nanomaterials Imaging Techniques, Surface Studies, and Applications by
Cover of the book Real Options and Strategic Technology Venturing by
Cover of the book Web 2.0 Technologies and Democratic Governance by
Cover of the book Hereditary Retinopathies by
Cover of the book Theory of Fuzzy Computation by
Cover of the book An Introduction to Inverse Limits with Set-valued Functions by
Cover of the book Historical Archaeology of Gendered Lives by
Cover of the book Molecular Basis for Therapy of AIDS-Defining Cancers by
Cover of the book Current Research in Acupuncture by
Cover of the book Mathematical and Numerical Foundations of Turbulence Models and Applications by
Cover of the book Biomechanics of the Human Body by
Cover of the book The Fundamentals of Atomic and Molecular Physics by
Cover of the book Nephrology Forum by
Cover of the book Time-Sensitive Remote Sensing by
Cover of the book Creating New Medical Ontologies for Image Annotation by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy